Saturday, February 16, 2019

Daiichi Sankyo to Colaborate with Merck KGaA and Pfizer in Development of Trastuzumab Deruxtecan

This week Daiichi Sankyo confirmed a clinical research collaboration with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate trastuzumab deruxtecan*, an antibody-drug conjugate or ADC also known as DS-8201, in combination with avelumab (Bavencio®; EMD Serono/Pfizer), a human anti-programmed death ligand-1 (PD-L1) antibody, and a novel, investigational DNA damage response (DDR) inhibitor in patients with human epidermal growth factor...

Study Confirms Local Radiotherapy to Improve Survival in Metastatic Prostate Cancer

According to recent data from the American Cancer Society, about 1 in 9 men will be diagnosed with prostate cancer during his lifetime and about 6 in 10 are diagnosed at aged 65 or older. Between 1990 and 2015, the incident of of prostate cancer increased 3.7-fold. In 2018 the United States about 164,690 men are diagnosed with a...

Addition of Pelvic Lymph Node Radiation may Significant Improve Prostate Cancer Treatment

Initial reports from a large international clinical trial suggest that, in the treatment of man with prostate cancer that recurs after prostatectomy, the surgical removal of the prostate gland, extending radiation therapy to the pelvic lymph nodes combined with adding short-term hormone therapy to standard treatment can extend the amount of time before their cancer spreads. These findings, presented at...

Cetuximab Causes Less Side Effects and May be a Good Treatment Option for HPV+ Throat Cancer

Over the last decades human papilloma virus (HPV-) positive throat cancer incidence is rapidly increasing worldwide while the incidence of head and neck squamous cancers overall has declined in developed countries. The incidence of throat cancer is rapidly becoming more common in Western countries. For example in the United Kingdom, incidence was unchanged in 1970 to 1995, then doubled in...

Study Shows Zoledronic Acid Improves Disease-free Survival in Premenopausal HR+ early Breast Cancer

Adjuvant treatment with the bone sparing drug zoledronic acid plus hormonal therapy with the aromatase inhibitor letrozole significantly increases disease-free survival compared to tamoxifen in premenopausal women with hormone receptor positive (HR+) early breast cancer. This is the conclusion of a study presented at European Society for Medical Oncology - ESMO 2018 Congress in Munich, Germany. It is the first...

Pembrolizumab Improves Survival of Patients with Metastatic or Recurrent Head and Neck Cancer

Late-breaking results from the KEYNOTE-048 study (NCT02358031) reported at the annual congress of the European Society for Medical Oncology - ESMO 2018, in Munich, Germany, show that immunotherapy with pembrolizumab (Keytruda®; Merck Sharp & Dohme, a subsidiary of Merck & Co), a humanized IgG4 isotype antibody targeting the programmed cell death 1 receptor (also known as PD-1 and CD279)...

Real-World Pancreatic Cancer Data Similar to Dosing Patterns Seen in Pivotal Trials

Results from a retrospective, observational analysis examining the real-world dosing patterns of patients with metastatic pancreatic cancer (mPC) treated with irinotecan liposome injection (Onivyde®, Ipsen Biopharmaceuticals, an affiliate of Ipsen) shows that in a real-world setting patients experienced similar dosing patterns as seen in the pivotal Phase III NAPOLI-1 clinical trial. The results were presented in a poster presentation at...

Nivolumab + Low-dose Ipilimumab may be First Line Treatment in Some Metastatic Colorectal Cancers

Immunotherapy with nivolumab (Opdivo®; Bristol-Myers Squibb Company) and low-dose ipilimumab (Yervoy®; Bristol-Myers Squibb Company) could become a new first line treatment in patients with some metastatic colorectal cancers following late-breaking results from the CheckMate-142 trial reported at the annual congress of the European Society for Medical Oncology - ESMO 2018, held in Munich, Germany. The results of the CheckMate-142...

Combination of DKN-01 and Pembrolizumab in Esophagogastric Cancer Shows Promise

Clinical data from from an ongoing Phase I/II study of DKN-01, being developed by Leap Therapeutics, in combination with pembrolizumab (Keytruda®; Merck/MSD) in patients with advanced esophagogastric cancer, presented at the annual congress of the European Society for Medical Oncology - ESMO 2018, taking  place October 19-23, 2018 in Munich, Germany, confirms promising clinical activity. DKN-01 is a humanized monoclonal...

Encouraging Results for [Fam-] Trastuzumab Deruxtecan in HER2 Expressing Advanced Colorectal Cancer

Updated Phase I safety and efficacy data for trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody-drug conjugate or ADC, were presented at the 2018 annual congress of the European Society for Medical Oncology - ESMO 2018, in Munich, Germany for a subgroup of patients with heavily pretreated HER2 expressing colorectal cancer. Colorectal cancer is the third most common cancer...

right side

ads

Related articles